BGC20-761 is a selecvtive 5-HT6 and dopamine receptor antagonist (human receptor K i values: 5-HT6 (20 nM), 5-HT2A (69 nM), D2 (140 nM). BGC20-761 is a tryptamine analog with a high affinity for 5-HT(6) receptors, that can enhance long-term memory. BGC20-761 has potential utility as an antipsychotic agent [1].

BGC20-761 is a highly efficient and selective 5-HT6 receptor antagonist; rat K i values for other rats receptors: 5-HT2A (470 nM), 5-HT2C (675 nM), D2, D3, D4, DAT and SERT (>10,000 nM) [1].

BGC20-761 enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks by a 5-HT6 receptor-mediated mechanism. BGC20-761 (2.5 mg/kg, 5 mg/kg and 10 mg/kg; i.p.) alone has no effect on social recognition in young rats, however, at doses of 5 mg/kg and 10 mg/kg i.p, BGC20-761 dose-dependently reverses a deficit of social recognition induced by Scopolamine (0.4 mg/kg i.p.) [1]. Animal Model: Forty-two male 8-week-old Longe Evans rats and 12 male four-week-old SpragueeDawley rats [1] Dosage: 2.5 mg/kg, 5 mg/kg and 10 mg/kg Administration: Administered (i.p.) immediately after the training session for the social recognition test Result: Administered alone did not show any difference in social recognition as compared to saline treated control animals. However, 5 mg/kg and 10 mg/kg reversed a Scopolamine induced deficit in social recognition.